Anti-angiogenic factor endostatin in osteosarcoma

Hyunsoo Kim, Sung Jig Lim, Yong Koo Park

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Neoplastic neovascularization is regulated not only by stimulators, but also by inhibitors of angiogenesis and might be the result of a net balance between the positive and negative regulators. Endostatin (ES) is a potent inhibitor of angiogenesis. The expression of ES has not been investigated in patients with osteosarcomas (OSAs). The aim of this study was to determine whether there is a correlation between the expression of ES and clinicopathologic parameters and/or outcomes in patients with OSAs. We made tissue microarrays from 46 cases of OSA and analyzed the expression of ES using immunohistochemistry. Staining was assessed in a semi-quantitative manner by scoring the proportion of positive tumor cells over the total number of tumor cells. A sample was defined as ES-positive when 10% or more of the tumor cells were stained positively throughout the tumor core. ES was localized to the cytoplasm of the tumor cells. 32.6% (15/46) of the patients were ES-positive. The expression of ES was positively correlated with tumor size (p = 0.011), histologic grade (p = 0.034), stage (p = 0.025), and distant metastasis (p = 0.036). Our results suggest that the expression of ES is increased in OSA, and ES may be used as a prognostic marker in patients with OSAs.

Original languageEnglish
Pages (from-to)716-723
Number of pages8
JournalAPMIS
Volume117
Issue number10
DOIs
Publication statusPublished - 2009 Oct 1

Fingerprint

Endostatins
Angiogenesis Inducing Agents
Osteosarcoma
Neoplasms
Angiogenesis Inhibitors
Cytoplasm
Cell Count
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Kim, Hyunsoo ; Lim, Sung Jig ; Park, Yong Koo. / Anti-angiogenic factor endostatin in osteosarcoma. In: APMIS. 2009 ; Vol. 117, No. 10. pp. 716-723.
@article{6f4904a1d58d40a69ec62ad2b478496f,
title = "Anti-angiogenic factor endostatin in osteosarcoma",
abstract = "Neoplastic neovascularization is regulated not only by stimulators, but also by inhibitors of angiogenesis and might be the result of a net balance between the positive and negative regulators. Endostatin (ES) is a potent inhibitor of angiogenesis. The expression of ES has not been investigated in patients with osteosarcomas (OSAs). The aim of this study was to determine whether there is a correlation between the expression of ES and clinicopathologic parameters and/or outcomes in patients with OSAs. We made tissue microarrays from 46 cases of OSA and analyzed the expression of ES using immunohistochemistry. Staining was assessed in a semi-quantitative manner by scoring the proportion of positive tumor cells over the total number of tumor cells. A sample was defined as ES-positive when 10{\%} or more of the tumor cells were stained positively throughout the tumor core. ES was localized to the cytoplasm of the tumor cells. 32.6{\%} (15/46) of the patients were ES-positive. The expression of ES was positively correlated with tumor size (p = 0.011), histologic grade (p = 0.034), stage (p = 0.025), and distant metastasis (p = 0.036). Our results suggest that the expression of ES is increased in OSA, and ES may be used as a prognostic marker in patients with OSAs.",
author = "Hyunsoo Kim and Lim, {Sung Jig} and Park, {Yong Koo}",
year = "2009",
month = "10",
day = "1",
doi = "10.1111/j.1600-0463.2009.02524.x",
language = "English",
volume = "117",
pages = "716--723",
journal = "Acta pathologica et microbiologica Scandinavica",
issn = "0365-5555",
publisher = "Blackwell Munksgaard",
number = "10",

}

Anti-angiogenic factor endostatin in osteosarcoma. / Kim, Hyunsoo; Lim, Sung Jig; Park, Yong Koo.

In: APMIS, Vol. 117, No. 10, 01.10.2009, p. 716-723.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-angiogenic factor endostatin in osteosarcoma

AU - Kim, Hyunsoo

AU - Lim, Sung Jig

AU - Park, Yong Koo

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Neoplastic neovascularization is regulated not only by stimulators, but also by inhibitors of angiogenesis and might be the result of a net balance between the positive and negative regulators. Endostatin (ES) is a potent inhibitor of angiogenesis. The expression of ES has not been investigated in patients with osteosarcomas (OSAs). The aim of this study was to determine whether there is a correlation between the expression of ES and clinicopathologic parameters and/or outcomes in patients with OSAs. We made tissue microarrays from 46 cases of OSA and analyzed the expression of ES using immunohistochemistry. Staining was assessed in a semi-quantitative manner by scoring the proportion of positive tumor cells over the total number of tumor cells. A sample was defined as ES-positive when 10% or more of the tumor cells were stained positively throughout the tumor core. ES was localized to the cytoplasm of the tumor cells. 32.6% (15/46) of the patients were ES-positive. The expression of ES was positively correlated with tumor size (p = 0.011), histologic grade (p = 0.034), stage (p = 0.025), and distant metastasis (p = 0.036). Our results suggest that the expression of ES is increased in OSA, and ES may be used as a prognostic marker in patients with OSAs.

AB - Neoplastic neovascularization is regulated not only by stimulators, but also by inhibitors of angiogenesis and might be the result of a net balance between the positive and negative regulators. Endostatin (ES) is a potent inhibitor of angiogenesis. The expression of ES has not been investigated in patients with osteosarcomas (OSAs). The aim of this study was to determine whether there is a correlation between the expression of ES and clinicopathologic parameters and/or outcomes in patients with OSAs. We made tissue microarrays from 46 cases of OSA and analyzed the expression of ES using immunohistochemistry. Staining was assessed in a semi-quantitative manner by scoring the proportion of positive tumor cells over the total number of tumor cells. A sample was defined as ES-positive when 10% or more of the tumor cells were stained positively throughout the tumor core. ES was localized to the cytoplasm of the tumor cells. 32.6% (15/46) of the patients were ES-positive. The expression of ES was positively correlated with tumor size (p = 0.011), histologic grade (p = 0.034), stage (p = 0.025), and distant metastasis (p = 0.036). Our results suggest that the expression of ES is increased in OSA, and ES may be used as a prognostic marker in patients with OSAs.

UR - http://www.scopus.com/inward/record.url?scp=70349320569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349320569&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0463.2009.02524.x

DO - 10.1111/j.1600-0463.2009.02524.x

M3 - Article

VL - 117

SP - 716

EP - 723

JO - Acta pathologica et microbiologica Scandinavica

JF - Acta pathologica et microbiologica Scandinavica

SN - 0365-5555

IS - 10

ER -